|
TW201014850A
(en)
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
JP5535931B2
(ja)
|
2008-10-27 |
2014-07-02 |
武田薬品工業株式会社 |
二環性化合物
|
|
EP2371826A4
(en)
|
2008-12-29 |
2012-06-27 |
Takeda Pharmaceutical |
NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
|
|
US20120172351A1
(en)
|
2009-06-09 |
2012-07-05 |
Nobuyuki Negoro |
Novel fused cyclic compound and use thereof
|
|
IN2012DN00954A
(enExample)
|
2009-07-28 |
2015-04-10 |
Takeda Pharmaceutical |
|
|
PL2464232T3
(pl)
|
2009-08-10 |
2016-04-29 |
Samumed Llc |
Indazolowe inhibitory szlaku sygnałowego Wnt i ich zastosowania terapeutyczne
|
|
US20110112158A1
(en)
*
|
2009-11-11 |
2011-05-12 |
David Robert Bolin |
Benzisoxazole analogs as glycogen synthase activators
|
|
US8450340B2
(en)
|
2009-12-21 |
2013-05-28 |
Samumed, Llc |
1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EA021698B1
(ru)
|
2010-04-27 |
2015-08-31 |
Такеда Фармасьютикал Компани Лимитед |
Производные бициклических соединений и их применение в качестве ингибиторов acc
|
|
PH12012502468A1
(en)
|
2010-06-16 |
2015-05-08 |
Takeda Pharmaceuticals Co |
Crystal of amide compound
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
EP2617726A4
(en)
|
2010-09-17 |
2014-05-14 |
Takeda Pharmaceutical |
DIABETES THERAPEUTIC
|
|
EP2649062B1
(en)
|
2010-11-30 |
2015-04-08 |
Takeda Pharmaceutical Company Limited |
Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
|
|
BR112013020634A2
(pt)
|
2011-02-17 |
2016-10-25 |
Takeda Pharmaceutical |
método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP3473099A1
(en)
|
2011-09-14 |
2019-04-24 |
Samumed, LLC |
Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9133129B2
(en)
|
2011-10-24 |
2015-09-15 |
Takeda Pharmaceutical Company Limited |
Bicyclic compound
|
|
JP6129850B2
(ja)
|
2012-01-12 |
2017-05-17 |
武田薬品工業株式会社 |
Mch受容体拮抗剤としてのベンゾイミダゾール誘導体
|
|
US9181186B2
(en)
|
2012-02-13 |
2015-11-10 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
EP2816023A4
(en)
|
2012-02-13 |
2015-09-09 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
WO2013122260A1
(en)
|
2012-02-15 |
2013-08-22 |
Takeda Pharmaceutical Company Limited |
Tablet
|
|
JP6106179B2
(ja)
|
2012-02-24 |
2017-03-29 |
武田薬品工業株式会社 |
芳香環化合物
|
|
CA2868713A1
(en)
|
2012-03-29 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
|
CN107417707A
(zh)
|
2012-05-04 |
2017-12-01 |
萨穆梅德有限公司 |
1H‑吡唑并[3,4‑b]吡啶及其治疗应用
|
|
EP2848621A4
(en)
|
2012-05-10 |
2016-06-01 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
EP2848622A4
(en)
|
2012-05-10 |
2015-11-04 |
Takeda Pharmaceutical |
Aromatic ring compound
|
|
AR092843A1
(es)
|
2012-06-05 |
2015-05-06 |
Takeda Pharmaceuticals Co |
Preparacion solida
|
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
|
WO2014110086A2
(en)
|
2013-01-08 |
2014-07-17 |
Samumed, Llc |
3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
|
|
JP6247697B2
(ja)
|
2013-03-14 |
2017-12-13 |
武田薬品工業株式会社 |
スピロアゼチジンイソキサゾール誘導体及びそのsstr5アンタゴニストとしての使用
|
|
WO2014165816A1
(en)
|
2013-04-05 |
2014-10-09 |
North Carolina Central University |
Compounds useful for the treatment of metabolic disorders and synthesis of the same
|
|
CA2917490A1
(en)
|
2013-07-09 |
2015-01-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
JP6397410B2
(ja)
|
2013-08-09 |
2018-09-26 |
武田薬品工業株式会社 |
芳香環化合物
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
US9428470B2
(en)
|
2014-02-13 |
2016-08-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
US9346776B2
(en)
|
2014-02-13 |
2016-05-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
|
CN104151216B
(zh)
*
|
2014-08-22 |
2016-08-17 |
山东铂源药业有限公司 |
一种拉帕替尼侧链的合成方法
|
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
|
US10221172B2
(en)
|
2015-01-13 |
2019-03-05 |
Vanderbilt University |
Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
US10604512B2
(en)
|
2015-08-03 |
2020-03-31 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
|
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
|
WO2017024010A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
|
EP3331870B1
(de)
|
2015-08-07 |
2021-06-16 |
Bayer CropScience Aktiengesellschaft |
2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel
|
|
NZ742200A
(en)
|
2015-11-06 |
2023-01-27 |
Samumed Llc |
Treatment of osteoarthritis
|
|
GB201604970D0
(en)
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
SI3464285T1
(sl)
|
2016-06-01 |
2023-02-28 |
Biosplice Therapeutics, Inc. |
Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
|
|
EP3528808B1
(en)
|
2016-10-21 |
2021-10-06 |
BioSplice Therapeutics, Inc. |
Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
|
|
KR102558716B1
(ko)
|
2016-11-07 |
2023-07-21 |
사뮤메드, 엘엘씨 |
단일-투여량, 즉시-사용가능한 주사용 제제
|
|
JOP20180029A1
(ar)
|
2017-03-30 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب حلقي غير متجانس
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
JOP20180028A1
(ar)
|
2017-03-31 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركب ببتيد
|
|
JPWO2018181847A1
(ja)
|
2017-03-31 |
2020-03-05 |
武田薬品工業株式会社 |
芳香環化合物
|
|
CN110117278B
(zh)
*
|
2018-02-07 |
2022-07-19 |
石家庄以岭药业股份有限公司 |
烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
|
|
EA202092269A1
(ru)
|
2018-03-23 |
2020-12-14 |
Кармот Терапьютикс, Инк. |
Модуляторы сопряженных с g-белком рецепторов
|
|
JP6773938B2
(ja)
|
2018-08-27 |
2020-10-21 |
株式会社スコヒアファーマ |
安息香酸エステル化合物
|
|
EP3856768A2
(en)
|
2018-09-24 |
2021-08-04 |
Takeda Pharmaceutical Company Limited |
Gip receptor agonist peptide compounds and uses thereof
|
|
EP3856339A1
(en)
|
2018-09-24 |
2021-08-04 |
Takeda Pharmaceutical Company Limited |
Gip receptor agonist peptide compounds and uses thereof
|
|
FI4097099T3
(fi)
|
2020-02-07 |
2024-07-30 |
Gasherbrum Bio Inc |
Heterosyklisiä glp-1-agonisteja
|
|
AR121649A1
(es)
|
2020-03-25 |
2022-06-22 |
Takeda Pharmaceuticals Co |
Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
|
|
AU2021241257A1
(en)
|
2020-03-25 |
2022-10-13 |
Takeda Pharmaceutical Company Limited |
QD dosing of GIP receptor agonist peptide compounds and uses thereof
|
|
PL4143183T3
(pl)
|
2020-04-29 |
2026-03-02 |
Gasherbrum Bio, Inc. |
Heterocykliczni agoniści glp-1
|
|
CN112062754B
(zh)
*
|
2020-09-24 |
2022-06-21 |
深圳市华先医药科技有限公司 |
一种合成Dorzagliatin的中间体的制备方法
|
|
WO2022078356A1
(zh)
*
|
2020-10-15 |
2022-04-21 |
山东轩竹医药科技有限公司 |
杂芳环类AhR抑制剂
|
|
CN112300028B
(zh)
*
|
2020-10-27 |
2022-03-11 |
无锡双启科技有限公司 |
一种2-氨基-3-甲氧基-5-溴苯腈的制备方法
|
|
EP4274824A1
(en)
*
|
2021-01-08 |
2023-11-15 |
IFM Due, Inc. |
Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
|
|
CN117980325A
(zh)
|
2021-05-13 |
2024-05-03 |
卡莫特治疗学股份有限公司 |
G-蛋白偶联受体的调节剂
|
|
CN116693519A
(zh)
|
2022-03-04 |
2023-09-05 |
上海璎黎药业有限公司 |
一种含五元杂芳环结构化合物、其药物组合物及应用
|
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
|
EP4496797A1
(en)
|
2022-03-21 |
2025-01-29 |
Gasherbrum Bio, Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
|
US20250250269A1
(en)
|
2022-04-14 |
2025-08-07 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2024112831A1
(en)
*
|
2022-11-22 |
2024-05-30 |
Maze Therapeutics, Inc. |
Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
|
|
JP2026501171A
(ja)
|
2022-12-15 |
2026-01-14 |
ガシャーブラム・バイオ・インコーポレイテッド |
Glp-1アゴニスト活性を有する化合物の塩および固体形態
|
|
EP4638455A1
(en)
|
2022-12-22 |
2025-10-29 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
EP4638440A1
(en)
|
2022-12-22 |
2025-10-29 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
AU2024222719A1
(en)
|
2023-02-16 |
2025-08-21 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
US20250019389A1
(en)
|
2023-06-30 |
2025-01-16 |
Gasherbrum Bio, Inc. |
Heterocyclic agonists
|
|
WO2025015269A1
(en)
|
2023-07-13 |
2025-01-16 |
Aconcagua Bio, Inc. |
Compounds, compositions, and methods
|
|
TW202521528A
(zh)
|
2023-07-13 |
2025-06-01 |
美商雅空嘉閣生物公司 |
化合物、組合物及方法
|
|
WO2025045208A1
(en)
|
2023-08-31 |
2025-03-06 |
Gasherbrum Bio, Inc. |
Heteroaryl-heterocycloalkyl-based glp-1 agonists
|
|
WO2025137307A1
(en)
|
2023-12-20 |
2025-06-26 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2025154020A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025154021A1
(en)
|
2024-01-19 |
2025-07-24 |
Takeda Pharmaceutical Company Limited |
Improved gip receptor agonist peptide compounds and uses thereof
|
|
WO2025171341A2
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
|
|
WO2025171340A1
(en)
|
2024-02-08 |
2025-08-14 |
Aconcagua Bio, Inc. |
The treatment of calcitonin- and/or amylin-receptor associated conditions
|
|
WO2026041075A1
(en)
|
2024-08-21 |
2026-02-26 |
Gasherbrum Bio, Inc. |
Gpl-1 agonists
|
|
WO2026051998A1
(en)
|
2024-09-04 |
2026-03-12 |
Aconcagua Bio, Inc. |
Compounds, compositions, and methods
|